Academic literature on the topic 'Oral medication Problems'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Oral medication Problems.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Oral medication Problems"
1
Agbor, Michael A., and Clement C. Azodo. "Self medication for oral health problems in Cameroon." International Dental Journal 61, no. 4 (August 2011): 204–9. http://dx.doi.org/10.1111/j.1875-595x.2011.00058.x.
Full text
2
Patsan, Irena, Amanda Tapley, Peter Davoren, Alison Fielding, Elizabeth Holliday, Jean Ball, Andrew Davey, et al. "Temporal trends in, and associations of, early-career general practitioner prescriptions of second-line Type 2 Diabetes medications, 2010–2018." PLOS ONE 18, no. 1 (January 20, 2023): e0280668. http://dx.doi.org/10.1371/journal.pone.0280668.
Full textAbstract:
Introduction Second-line pharmacotherapy for Type 2 Diabetes Mellitus (‘diabetes’) is necessary for optimal glycaemic control and preventing longer-term complications. We aimed to describe temporal trends in, and associations of, Australian general practitioner (GP) registrars’ prescription, and initiation, of ‘new’ second-line oral agents (dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists) compared to sulphonylureas. Materials and methods A longitudinal analysis (2010–2018) of data from the Registrar Clinical Encounters in Training project. Analysis included any diabetes problem/diagnosis that involved prescription of sulphonylureas or ‘new’ oral agents. Simple and multiple logistic regression models were fitted within the generalised estimating equations framework. Results 2333 registrars recorded 6064 diabetes problems/diagnoses (1.4%). 835 problems/diagnoses involved sulphonylurea or ‘new’ medication prescription. Of these, 61.0% [95% CI:57.4–64.4] involved ‘new’ medication prescription. 230 problems/diagnoses involved sulphonylurea or ‘new’ medication initiation, with 77% [95%CI:70.8–82.1] involving a ‘new’ medication. There was a significant 52% per year increase in prescribing (OR = 1.52[95% CI:1.38–1.68],p<0.001), and a 77% per (two-to-three-year) time-interval increase in initiation (OR = 1.77,[95% CI:1.30–2.43],p = <0.001) of ‘new’ medications compared to sulphonylureas. ‘New’ medications were prescribed less for non-English-speaking patients. There was some regional variation in prescribing. Conclusion Registrar uptake of ‘new’ oral agents compared to sulphonylureas has increased rapidly.
3
Pop-Jordanova, Nada, and Sofija Loleska. "On Psychosomatic Problems in Dentistry." PRILOZI 41, no. 1 (June 1, 2020): 57–63. http://dx.doi.org/10.2478/prilozi-2020-0023.
Full textAbstract:
AbstractIn their daily practice dentists frequently have patients showing signs of stress-related oral manifestations in different forms. Stress-related aetiology of oral changes are still not investigated enough, and present a subgroup of psychosomatic diseases which had been recognized in medicine a long time ago. Recognition of such psychological or emotional disturbance needs deep evaluation “per exclusionem”, and is beneficial for both the patient and clinician. Psychological management should be taken into consideration when treating patients with these psychosomatic disorders. Therapeutic approach comprises different forms of psychotherapy and medication as well.
4
Broers, Barbara, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, and Sophie Pautex. "Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva." Medical Cannabis and Cannabinoids 2, no. 1 (April 4, 2019): 56–59. http://dx.doi.org/10.1159/000498924.
Full textAbstract:
Background: Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective: To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/CBD-based oral medication in severely demented patients in a specialized nursing home in Geneva. Methods: This was a prospective observational study. Results: Ten female demented patients with severe behavior problems received oral medication with on average 7.6 mg THC/13.2 mg CBD daily after 2 weeks, 8.8 mg THC/17.6 mg CBD after 1 month, and 9.0 mg THC/18.0 mg CBD after 2 months. The THC/CBD-based oil was preferred. Neuropsychiatric Inventory, Cohen-Mansfield Agitation Inventory score, and a behavior problem visual analog scale decreased by 40% after 2 months, rigidity score by 50%. Half of the patients decreased or stopped other psychotropic medications. The staff appreciated the decrease in rigidity, making daily care and transfers easier, the improved direct contact with the patients, the improvement in behavior, and the decrease in constipation with less opioids. There was no withholding of the medication for reasons of side effects, and the effects persisted after 2 months. Conclusions: An oral cannabis extract with THC/CBD, in higher dosages than in other studies, was well tolerated and greatly improved behavior problems, rigidity, and daily care in severely demented patients.
5
Dubey, Pragati, and Neelam Mittal. "Assessment of self-medication practice for oral health problems among people of Varanasi, Uttar-Pradesh, India." International Journal Of Community Medicine And Public Health 9, no. 6 (May 27, 2022): 2660. http://dx.doi.org/10.18203/2394-6040.ijcmph20221550.
Full textAbstract:
Background: Self medication has been practiced for centuries in both industrialized and under developed countries. There are lots of literatures indicating people awareness regarding abuse of medicines and antibiotics without a doctor’s prescription, but there has not been much study conducted for dental illness. The present study aimed to gather information about self-medication pattern among people of Varanasi, Uttar-Pradesh and to identify the measures to curb these life-threatening practices.Methods: An observational based cross-sectional study was carried out in OPD of Faculty of Dental Sciences, IMS, BHU, Varanasi. The sample size comprised of 500 respondents. The SPS software was used to code, input, and analyze all descriptive data. Descriptive data analysis was performed and the results were provided as frequencies and percentage.Results: The response of survey received a perfect score of 100%. The prevalence rate of self medication was found to be 56.2%. The main reason for engaging in such life threatening practice was lack of time and ignorance. Analgesia was the most commonly utilized type of medication. Out of 281, 84 patients sought basic care from a pharmacist, whereas 49.2% patient approached to visit dentist only when their problem continued.Conclusions: The prevalence rate was higher in male than female. Controlling self-medication requires patient health awareness initiatives, community pharmacist help, and pharmacist continuing education. There is a need for intervention planning to encourage rational self-medication through mass media such as newspapers, magazines and TV.
6
Dürr, Pauline, Katja Schlichtig, Carolin Kelz, Birgit Deutsch, Renke Maas, Michael J. Eckart, Jochen Wilke, et al. "The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents." Journal of Clinical Oncology 39, no. 18 (June 20, 2021): 1983–94. http://dx.doi.org/10.1200/jco.20.03088.
Full textAbstract:
PURPOSE Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer therapy. However, considerable challenges regarding medication safety of oral anticancer drugs have been reported. Randomized, controlled, multicenter studies on the impact of intensified clinical pharmacological/pharmaceutical care on patient safety and patient treatment perception are lacking. METHODS Patients were eligible for the randomized, multicenter AMBORA study, if they were newly started on any of the oral anticancer drugs approved in 2001 or later without restriction to certain tumor entities. Patients were randomly assigned to receive either standard of care (control group) or an additional, intensified clinical pharmacological/pharmaceutical care, which included medication management and structured patient counseling, over a period of 12 weeks (intervention group). Primary end points were the number of antitumor drug–related problems (ie, side effects and unresolved medication errors) and patient treatment satisfaction with the oral anticancer therapy after 12 weeks measured with the Treatment Satisfaction Questionnaire for Medication, category convenience. RESULTS Two hundred two patients were included. Antitumor drug–related problems were significantly lower in the intervention compared with the control group (3.85 v 5.81 [mean], P < .001). Patient treatment satisfaction was higher in the intervention group (Treatment Satisfaction Questionnaire for Medication, convenience; 91.6 v 74.4 [mean], P < .001). The hazard ratio for the combined end point of severe side effects (Common Terminology Criteria for Adverse Events ≥ 3), treatment discontinuation, unscheduled hospital admission, and death was 0.48 (95% CI, 0.32 to 0.71, P < .001) in favor of the intervention group. CONCLUSION Treatment with oral anticancer drugs is associated with a broad range of medication errors and side effects. An intensified clinical pharmacological/pharmaceutical care has considerable, positive effects on the number of medication errors, patient treatment perception, and severe side effects.
7
Ju Lee, Bong, Lyang Huh, and Hyun Ju Lee. "T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS." Schizophrenia Bulletin 46, Supplement_1 (April 2020): S313. http://dx.doi.org/10.1093/schbul/sbaa029.771.
Full textAbstract:
Abstract Background Long-acting antipsychotic therapy (LAT) may help effectively manage individuals with schizophrenia by optimizing adherence, improving treatment response, reducing the risk of relapse, and improving long-term outcomes. LAT has an established role in the maintenance treatment of chronic, poorly adherent, and/or severely ill patients in later stages of schizophrenia. It is not yet known whether the positive effects of these LATs are merely on the control of symptoms and preventing relapse or on changes in insights and attitudes to medications, resulting in changes in disease course. Methods This retrospective, single-center study was conducted within the Department of Psychiatry at Inje University Haeundae Paik Hospital. To investigate the efficacy of LAT on the disease course, we compared re-hospitalization rate, drug attitude inventory (DAI), and The Positive and Negative Syndrome Scale (PANSS) in individuals with schizophrenia who had treated with once-monthly paliperidone palmitate and then switched to oral antipsychotics. Results A total of 105 patients changed from oral drugs to LAI. Of these, 31 patients were later changed to oral medication. Of the total LAI patients, 32 patients received less than 5 months a week. Thirteen patients were hospitalized for 6 months before LAI change and 3 patients were re-hospitalized during the maintenance period after LAI change. Three patients who did not have hospitalized for 6 months after the change of oral medication but did not have hospitalized during LAI maintenance period were re-hospitalized after changing to oral medication. Of the 72 patients who maintained the LAI for more than 5 months, 28 patients experienced re-hospitalization during oral medication before LAI, 9 of whom were re-hospitalized during the LAI. All of them kept on LAI. Seven patients who changed to oral medication during maintenance were not hospitalized during the maintenance period, but three patients were hospitalized after changing to oral medication. Of the 92 patients who had never been hospitalized within 6 months before the change of LAI, 14 had re-hospitalized after changing to LAI. However, none of the 92 patients who had never been hospitalized changed to oral medication. Regardless of the length of time, 5 (about 16%) were re-hospitalized in 31 patients who changed from LAI to the oral medication again. Interestingly, the patients were not hospitalized during the LAI period. There were 27 dropouts. Twenty patients (19%) after LAI change and 7 patients (6%) after oral change. There was no statistical difference in DAI and PANSS scores after the change from LAI to oral medication. Discussion As previously known, the inhibition effect of relapse was evident during the LAI period. There was no change in adherence to medication, attitudes toward treatment, and degree of illness within 6 months. There were 27 dropouts. Twenty patients (19%) after LAI change and seven patients (6%) after oral change. It has been a long time since the onset, and 7 patients have moved to the hospital. Most of these seven patients were considered to be the case of compliance problems. Immediately after the change of oral medication, dropout occurred in 4 patients, and the duration of LAI in these patients was 2–5 months. The lack of statistical difference between DAI and PANSS after changing to oral drug in LAI can be attributed to the short interval of 6 months.
8
Maciejewski, Matthew L., Bradley G. Hammill, Corrine I. Voils, Laura Ding, Elizabeth A. Bayliss, Lesley H. Curtis, and Virginia Wang. "Prescriber continuity and medication availability in older adults with cardiometabolic conditions." SAGE Open Medicine 6 (January 1, 2018): 205031211875738. http://dx.doi.org/10.1177/2050312118757388.
Full textAbstract:
Background: Many older adults have multiple conditions and see multiple providers, which may impact their use of essential medications. Objective: We examined whether the number of prescribers of these medications was associated with the availability of medications, a surrogate for adherence, to manage diabetes, hypertension or dyslipidemia. Methods: A retrospective cohort of 383,145 older adults with diabetes, hypertension or dyslipidemia in the US Medicare program living in 10 states. The association between the number of prescribers of cardiometabolic medications in 2010 and medication availability (proportion of days with medication on hand) in 2011 was estimated via logistic regression, controlling for patient demographic characteristics and chronic conditions. Results: Medicare beneficiaries with diabetes, hypertension and/or dyslipidemia had an average of five chronic conditions overall, obtained 10–12 medications for all conditions and most often had one prescriber of cardiometabolic medications. In adjusted analyses, the number of prescribers was not significantly associated with availability of oral diabetes agents but having more prescribers is associated with increased medication availability in older Medicare beneficiaries with dyslipidemia or hypertension. Conclusion: The incremental addition of new prescribers may be clinically reasonable for complex patients but creates the potential for coordination problems and informational discontinuity over time. Health systems may want to identify complex patients with multiple prescribers to minimize care fragmentation.
9
Johnson, D. A. W. "Historical perspective on antipsychotic long-acting injections." British Journal of Psychiatry 195, S52 (November 2009): s7—s12. http://dx.doi.org/10.1192/bjp.195.52.s7.
Full textAbstract:
BackgroundClinical experience has shown considerable potential benefits from long-term continuous medication for chronic or relapsing forms of schizophrenia. These benefits have not always been realised.AimsTo review the research literature in order to understand the problems of long-term medication and use of antipsychotic oral medication and long-acting injections (LAIs), and to place these in an historical context.MethodReview of literature.ResultsResearch showed that the potential success of LAI therapy depends on the quality of the follow-up service.ConclusionsFollowing the advent of second-generation oral antipsychotics confidence in the use of LAIs has eroded and that mistakes made in LAI use during the past century may be repeated.
10
Butt, Hira, Samra Liaqat, Aqsa, Amna Nauman Khan, Nauman Rauf Khan, and Fizza Tahir. "Association of Sociodemographic Factors with Trends of Self-Medication Practice and Its Hazard Perception for Oral Health Problems among Patient." Journal of Gandhara Medical and Dental Science 9, no. 2 (April 6, 2022): 43–50. http://dx.doi.org/10.37762/jgmds.9-2.159.
Full textAbstract:
OBJECTIVES: To assess the impact of sociodemographic factors with the trends of self-medication practice and its hazard perception among patients METHODOLOGY: A cross sectional descriptive study was conducted on the patients visiting Sharif Medical and Dental College from June 2019 to June 2020. Data was collected using a validated questionnaire from 142 patients. Chi-square and fisher exact tests were used to find the association of trends of self-medication practice and hazard perception with sociodemographic factors. RESULTS: The patients in the age range of 18 to 29 years practiced self-medication the most. The triggering factor for use of medication was toothache among all ages. The most commonly used drug was reported to be analgesics. The main reason for self-medication was lack of time to visit the doctor. The females practiced self-medication more than the males. The triggering factor for both the genders was toothache and analgesics were mostly used. The patients with tertiary level education and those who were unemployed practiced self- medication the most. The triggering factor was toothache across all levels of education and employed as well as unemployed patients. Drug resistance was stated the main hazard. CONCLUSION: The triggering factor for use of medication was toothache, most commonly used drugs were analgesics and the main reason for self-medication was lack of time across all ages, both the gender, married and unmarried patients, levels of education and employment. Un-employed patients and those with tertiary level of education-practiced self- medicated themselves the most. The highest percentage of patients considered drug resistance to be the biggest hazard.
Dissertations / Theses on the topic "Oral medication Problems"
1
Boardman, Gayelene. "A problem-solving based peer support program for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia." Thesis, 2012. https://vuir.vu.edu.au/22356/.
Full textAbstract:
Many people with schizophrenia are reluctant to take their antipsychotic medications, and this might have adverse implications for their recovery. Numerous approaches have been implemented to enhance medication taking for this population, but results have varied. The overall aim of the study was to assess if consumers with schizophrenia had improved adherence to their oral antipsychotic medication after participation in a problem-solving based peer support program.
Book chapters on the topic "Oral medication Problems"
1
Nair, Sanjiv, and Sunil S. Shroff. "Vascular Anomalies of the Oro-Maxillofacial Region." In Oral and Maxillofacial Surgery for the Clinician, 629–58. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-1346-6_31.
Full textAbstract:
AbstractVascular anomalies is a diverse group of disorders involving the vasculature (arteries,veins and lymphatics). These lesions in the head and neck can present since birth or later in life causing functional, cosmetic and bleeding problems. They can sometimes co-exist with a wide array of other pathologies and components of various syndromes. The different types, classifications, clinical features, imaging characteristics, treatment options and complications will be discussed in detail, with accordance to guidelines and principles in current literature. The author has designed a widely accepted anatomical classification for surgical management of these complex lesions, which is discussed in depth. Tailoring therapy depending on the anomaly is the key to successful treatment. Hemangiomas tend to proliferate and then involute , hence treated with systemic medication or alternate therapy for residual lesions. Vascular Malformations essentially would require aggressive management with surgery or embolisation and surgery. The concept of ‘corset suturing’ is explained and described, which is thought to be the ideal management for large venous malformations.
2
Hägg, Mary, and Natalie R. Morris. "Introducing IQoro: A Clinically Effective Oral Neuromuscular Treatment for Dysphagia." In Dysphagia - New Advances. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101144.
Full textAbstract:
There is a clear need for new advances in treating dysphagia; healthcare professionals currently have a restricted range of options to treat swallowing problems and related conditions. Usual treatments for dysphagia are based on compensatory measures which allow patients to live within the limitations of their condition. These measures do not address the underlying cause of dysphagia: neurological and physiological dysfunction. A senior speech and language therapist working with young people with Cerebral Palsy bemoans the fact that official care pathway guidelines list only medication and surgical intervention as alternatives to treat drooling. Neither of which, she contends, is effective or desirable. Esophageal dysphagia causes reflux-based diseases, which are also poorly served by current treatment alternatives and are currently managed by medication, or remedied by surgical intervention. Medication reduces the symptoms of reflux but does nothing to address the underlying pathophysiology, muscular dysfunction, at the root of the problem. That now changes with IQoro: a simple, innovative treatment that is available to patients and healthcare professionals to address all of the above conditions. The chapter explains the physiological and neurological process of the functional swallow in detail, with illustrations and explanations. The efficacy of IQoro treatment is proven with evidence from internationally published scientific studies, case studies, an NHS service evaluation, and NICE briefings.
3
Davidson, Mayer. "Case 72: Delayed Response to NPH Insulin By Mayer B. Davidson, MD." In Diabetes Case Studies: Real Problems, Practical Solutions, 267–70. American Diabetes Association, 2015. http://dx.doi.org/10.2337/9781580405713.72.
Full textAbstract:
A 58-year-old lean woman with type 2 diabetes was referred to the diabetes clinic for control of her diabetes. Diabetes was diagnosed 12 years ago and she had been taking insulin for 1 year after failing oral medication. Her insulin regimen at the time of referral was 20 units of NPH insulin before breakfast and 12 units before supper. Her BMI was 25.1 kg/m2 and her HbA1c level was 9.5%. She was motivated to improve her control. Table 72.1 summarizes our initial experience with her. Glucose values (mg/dL) are the range (median). The interval between visits was 3 weeks unless otherwise noted.
4
Akhter, Naheed, Sadia Sana, Naila Iftikhar, Muhammad Adnan Ahsan, Abu Huraira, and Zafaar Siddique. "Polycystic Ovary Syndrome: It’s Not Just Infertility." In Polycystic Ovary Syndrome [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101923.
Full textAbstract:
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine issue described by unpredictable menses, hyperandrogenism, and polycystic ovaries (PCO). The commonness of PCOS changes relying upon which measures are utilized to conclude yet is just about as high as 15–20% when the European culture for human propagation and embryology/American culture for regenerative medication rules are utilized. Clinical signs incorporated grown-ups incorporate sort 1 diabetes, type 2 diabetes, and gestational diabetes. Insulin opposition influences half 70% of ladies with PCOS prompting a few comorbidities including metabolic condition, hypertension, dyslipidemia, glucose narrow-mindedness, and diabetes. Studies show that ladies with PCOS are bound to have expanded coronary corridor calcium scores and expanded carotid intima-media thickness. Psychological wellness problems including despondency, uneasiness, bipolar turmoil, and voraciously consuming food issues additionally happen all the more habitually in ladies with PCOS. Weight reduction works on feminine abnormalities, indications of androgen abundance, and barrenness the board of clinical appearances of PCOS incorporates oral contraceptives for feminine inconsistencies and hirsutism. Spironolactone and finasteride are utilized to treat indications of androgen overabundance.
5
Tappuni, Anwar R. "Oral manifestations and management." In Oxford Textbook of Sjögren's Syndrome, edited by Elizabeth J. Price and Anwar R. Tappuni, 81–86. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198806684.003.0011.
Full textAbstract:
Low salivary flow rate is a significant problem in Sjögren’s syndrome (SS), which can affect patients’ general and oral health and well-being. Successful management of the long-term effects on oral health requires a systematic approach in assessing the severity of the oral dryness and the signs and symptoms of salivary gland dysfunction to enable clinicians to implement protective and palliative measures to SS patients to achieve oral comfort and adequate oral function. The use of topical fluoride for preventing dental caries and topical oral products or a cholinergic agonist medication for the relief of the dryness symptoms is recommended in the National Institute for Health and Care Excellence–approved guidelines for the management of SS.
6
Paykina, Natalya, Laurence L. Greenhill, and Jack M. Gorman. "Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder." In A Guide to Treatments that Work, 29–70. Oxford University Press, 2007. http://dx.doi.org/10.1093/med:psych/9780195304145.003.0002.
Full textAbstract:
More than 225 placebo-controlled Type 1 investigations demonstrate that psychostimulants—a group of ethylamines including methylphenidate and amphetamine—are highly effective in reducing core symptoms of childhood attention-deficit/hyperactivity disorder (ADHD) in preschoolers, school-age children, adolescents, and adults. Approximately 70% of patients respond to these medications in double-blind trials compared with 13% assigned to placebo. Short-term efficacy is more pronounced for behavioral rather than cognitive and learning abnormalities associated with ADHD. The stimulant treatment evidence base has been supplemented by two large multisite randomized controlled trials (RCTs)—the Multimodal Treatment Study of ADHD (MTA Study) and the Preschool ADHD Treatment Study (PATS)—that further support the short-term efficacy in young children. This study, plus the 1998 NIH Consensus Development Conference on ADHD, and the publication of the McMaster Evidence Based Review of ADHD Treatments (Jahad et al., 1999) emphasized the large evidence base supporting the efficacy of stimulant treatments. These medications are now available in long-duration preparations that allow for once-daily oral dosing, and they may even be sprinkled on food to accommodate children who cannot swallow pills. RCTs conducted more recently than 1998 continue to report a few key adverse events associated with stimulants—insomnia, decreased appetite, stomachache, and headache—but have not supported rarer and unexpected problems, such as visual hallucinations, cardiovascular accidents, or sudden unexpected death, reported anecdotally in the Food and Drug Administration’s Adverse Event Report System (AERS) MedWatch. Although these ADHD medications have been shown to retain their efficacy for as long as 14 months, concern remains that the long-term academic and social benefits have not yet been adequately assessed. Other nonstimulant agents for which there is limited evidence of efficacy include atomoxetine, modafinil, the tricyclics, bupropion, clonidine, and venlafaxine.